Search results
Author(s):
Cecilia Low Wang
Added:
2 years ago
Dr Cecilia Low Wang (Colorado Prevention Center, US) discusses the findings from the VOYAGER PAD - rivaroxaban in symptomatic PAD with and without comorbid diabetes study. The study assessed the efficacy and safety of rivaroxaban in patients with PAD with concomitant diabetes after lower extremity revascularization.
The study presented at ESC Congress 2021 showed that the efficacy of rivaroxaban…
View more
Author(s):
E Magnus Ohman
Added:
3 years ago
GEMINI-ACS - Comparison of the Safety of Rivaroxaban Versus Aspirin in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome.
Interview with Professor E. Magnus Ohman from Duke University Medical Center, Durham, North Carolina, USA at ACC 2017.
View more
Author(s):
Naima Maqsood
,
Christian Ruff
Added:
4 months ago
AHA 23 - Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews Dr Christian Ruff (Brigham and Women's Hospital, US) on the late-breaking findings from the AZALEA-TIMI 71 randomized trial (Anthos Theraputics, Inc).AZALEA-TIMI 71 aimed to evaluate the bleeding profile of abelacimab as compared to rivaroxaban in patients with atrial fibrillation who are at moderate to…
View more
Author(s):
Michael C Gibson
Added:
5 years ago
Dr C. Michael Gibson (Beth Israel Deaconess Medical Center, Boston, MA, US) discusses Rivaroxaban 2.5 mg BID combined with DAPT for the prevention of death/MI/stroke - a patient level data meta-analysis of the ATLAS-ACS-2 TIMI-51 and the COMMANDER HF trials
Filmed on site at CRT 2019 by Radcliffe Cardiology
Questions:
1. Why did you conduct this analysis?
2. How was data collected and…
View more
Author(s):
Josep Gradolí
,
Verónica Vidal
,
Adrian JB Brady
,
et al
Added:
3 years ago
Atherosclerotic cardiovascular disease (CVD) comprises a large number of related pathologies, including ischaemic heart disease and peripheral arterial disease (PAD).1 This group of illnesses is the main cause of global morbidity and mortality and its prevalence increases remorselessly.2
Despite implementation of guideline-based therapy and optimal medical treatment, patients with established…
View more
Author(s):
Han Naung Tun
,
May Thu Kyaw
,
Erik Rafflenbeul
,
et al
Added:
1 year ago
Author(s):
Minh That Ton
,
Tri Huynh Quang Ho
,
Viet Lan Nguyen
,
et al
Added:
3 months ago
Author(s):
Gheorghe-Andrei Dan
,
Adrian Catalin Buzea
Added:
3 years ago
Non-antivitamin K oral anticoagulants (NOACs) are no longer ‘new’ drugs: they already are established. Since randomised controlled trials (RCTs) usually enrol highly selected patient populations, the best way to demonstrate new drug efficiency/cost-effectiveness is to use long-term and ‘real-world’ data. In order to understand the NOAC experience in real life properly, one must first understand…
View more
Author(s):
Julia Sikorska
,
James Uprichard
Added:
3 years ago
For more than 50 years, oral vitamin K antagonists (VKAs) were the choice of anticoagulant for the long-term treatment and prevention of arterial and venous thromboembolic events (VTE). VKA treatment is safe and effective, if a high time in therapeutic range is achieved. However, achieving a stable, therapeutic international normalised ratio can prove challenging in the context of drug and food…
View more
Author(s):
Mahmoud Abdelnabi
,
Abdallah Almaghraby
,
Yehia Saleh
Added:
3 years ago
Vitamin K antagonist (VKA) oral anticoagulants have been ruling the field of anticoagulation for cardiovascular indications for years now. Recently, this dominance has been threatened by the introduction of direct oral anticoagulants (DOACs), with abundant data highlighting their safety and efficacy. To date, recent guidelines have limited the use of DOACs to stroke prevention in patients with…
View more